Study Human Digital Support Transitional Care (SUNH-ST)

Contribution of a Digital Tool Combined With Supportive Human Coordination for Transitional Care of Patients in Unscheduled Hospitalisation in Geriatric Short-stay Care

The purpose of the study is to compare the effectiveness of Divomed in organising complex hospital discharges with a conventional organisation. Effectiveness will be assessed by reducing the length of stay of patients in geriatric short-stay care.

Study Overview

• Status: Not yet recruiting
• Conditions: Aging
• Intervention / Treatment: Procedure: Unscheduled hospital admissions

Detailed Description

This is an interventional, randomised (ratio 1:1), single-centre, open-label study evaluating Divomed, a digital tool combined with human coordination, to speed up the discharge of people aged over 75 from unscheduled short-stay geriatric hospital admissions to their homes.

The study population will be patients aged 75 or over, admitted for short term unscheduled geriatric hospitalisation and eligible for discharge home.

• Study Type: Interventional
• Enrollment (Estimated): 150
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Wassim GANA; Phone Number: +33 247474747; Email: w.gana@chu-tours.fr

Study Locations

• France
  • Tours, France, 37044
    • CHRU de Tours - Hôpital Bretonneau
    • Contact: Wassim GANA, MD; Email: w.gana@chu-tours.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 75 years ;
• Unplanned hospitalisation from emergency, transfers from other inpatient departments or outpatient medicine;
• Patient eligible for short-stay geriatric hospitalisation estimated to last at least 10 days;
• Patient eligible for a return home;
• Patients who have been informed and have signed an informed consent form. If necessary (for cognitive or other reasons), the information must be given to a third party, i.e. the patient's legal representative or trusted person (independent of the investigator and the sponsor), who may be asked to sign or co-sign the informed consent form (depending on the patient's vulnerability).

Exclusion Criteria:

• Patients scheduled for transfusion, iron infusion or colonoscopy;
• Patients in palliative care;
• Geographical area other than department 37;
• Planned discharge from hospital to a residential establishment for dependent elderly people or to follow-up and rehabilitation care or long-term care units;
• Patient or deprived of liberty by judicial or administrative decision ;
• Patient participating in or being excluded from another clinical trial;
• Patients not covered by a social security scheme.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Divomed digital tool combined with human coordination; A digital tool combined with human coordination (Divomed) to organise discharge home from the start of hospitalisation. The digital application will be interconnected with the patient's medical file.	Procedure: Unscheduled hospital admissions; Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes
Active Comparator: Control Group; The control group corresponds to the organisation of conventional hospital discharge from the geriatric short-stay department. The digital application will be interconnected with the patient's medical file.	Procedure: Unscheduled hospital admissions; Unscheduled short-stay geriatric hospitalisations of people aged over 75 to their homes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
length of stay	The effectiveness of Divomed in organising complex hospital discharges will be assessed at discharge by comparing lengths of stay in the 2 groups.	1 month

Collaborators and Investigators

• Sponsor: Divoluci

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2024
• Primary Completion (Estimated): March 1, 2025
• Study Completion (Estimated): March 1, 2025

Study Registration Dates

• First Submitted: April 3, 2024
• First Submitted That Met QC Criteria: April 3, 2024
• First Posted (Actual): April 9, 2024

Study Record Updates

• Last Update Posted (Actual): April 9, 2024
• Last Update Submitted That Met QC Criteria: April 3, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 2023-A02745-40

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No